Alexander Chye1, Chung-Wei Christine Lin2,3, Mark J Hancock4, Ian Harris5, Jane Latimer2,3, Christopher G Maher2,3, Andrew J McLachlan6, Stephanie Mathieson2,3, Bart Koes7,8, Richard O Day9, Laurent Billot10, Stephen Jan10, Blake Angell10. 1. The George Institute for Global Health, University of New South Wales, Level 5, 1 King Street, Newtown, Sydney, 2041, Australia. achye@georgeinstitute.org.au. 2. The Institute for Musculoskeletal Health, Sydney, Australia. 3. Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia. 4. Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, Australia. 5. South Western Sydney Clinical School, University of New South Wales, Sydney, Australia. 6. Sydney Pharmacy School, The University of Sydney, Sydney, Australia. 7. Department of General Practice, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands. 8. Center for Muscle and Joint Health, University of Southern Denmark, Odense, Denmark. 9. St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, Sydney, Australia. 10. The George Institute for Global Health, University of New South Wales, Level 5, 1 King Street, Newtown, Sydney, 2041, Australia.
Abstract
PURPOSE: To estimate the healthcare resource utilisation of an Australian cohort of people with sciatica and explore individual-level factors associated with expenditure. METHODS: Healthcare utilisation (services and medication) data from a randomised, double-blind, placebo-controlled trial of pregabalin in patients with sciatica (n = 185) were analysed to estimate healthcare expenditure of participants over 12 months. Associations between key baseline socio-economic, pain and quality of life characteristics and healthcare expenditure were examined using generalised linear imputation models. RESULTS: On average, participants accessed AUD$1,134 of healthcare over the year, predominantly made up of $114 of medication and $914 of health services, which included $418 of physiotherapy services. Participants randomised to receive pregabalin incurred higher expenditure ($1,263 compared to $1,001 for placebo), which was largely driven by pregabalin ($158) and greater health services ($107). Healthcare expenditure was significantly higher for participants prescribed pregabalin, earning greater than $1,700 per week ($88,400 per year) and reporting poorer quality of life (physical and mental). CONCLUSION: Our results suggest inefficiency in the use of healthcare resources due to increased healthcare resource utilisation in people with sciatica treated withpregabalin, compared to placebo. Costs of treating sciatica varied based on individual quality of life and socio-economic characteristics.
RCT Entities:
PURPOSE: To estimate the healthcare resource utilisation of an Australian cohort of people with sciatica and explore individual-level factors associated with expenditure. METHODS: Healthcare utilisation (services and medication) data from a randomised, double-blind, placebo-controlled trial of pregabalin in patients with sciatica (n = 185) were analysed to estimate healthcare expenditure of participants over 12 months. Associations between key baseline socio-economic, pain and quality of life characteristics and healthcare expenditure were examined using generalised linear imputation models. RESULTS: On average, participants accessed AUD$1,134 of healthcare over the year, predominantly made up of $114 of medication and $914 of health services, which included $418 of physiotherapy services. Participants randomised to receive pregabalin incurred higher expenditure ($1,263 compared to $1,001 for placebo), which was largely driven by pregabalin ($158) and greater health services ($107). Healthcare expenditure was significantly higher for participants prescribed pregabalin, earning greater than $1,700 per week ($88,400 per year) and reporting poorer quality of life (physical and mental). CONCLUSION: Our results suggest inefficiency in the use of healthcare resources due to increased healthcare resource utilisation in people with sciatica treated with pregabalin, compared to placebo. Costs of treating sciatica varied based on individual quality of life and socio-economic characteristics.
Authors: R Lewis; N Williams; H E Matar; N Din; D Fitzsimmons; C Phillips; M Jones; A Sutton; K Burton; S Nafees; M Hendry; I Rickard; R Chakraverty; C Wilkinson Journal: Health Technol Assess Date: 2011-11 Impact factor: 4.014
Authors: Rose Crossin; Debbie Scott; Shalini Arunogiri; Karen Smith; Paul M Dietze; Dan I Lubman Journal: Med J Aust Date: 2018-11-22 Impact factor: 7.738
Authors: Stephanie Mathieson; Christopher G Maher; Andrew J McLachlan; Jane Latimer; Bart W Koes; Mark J Hancock; Ian Harris; Richard O Day; Laurent Billot; Justin Pik; Stephen Jan; C-W Christine Lin Journal: N Engl J Med Date: 2017-03-23 Impact factor: 91.245
Authors: Stephanie Mathieson; Christopher G Maher; Andrew J McLachlan; Jane Latimer; Bart W Koes; Mark J Hancock; Ian Harris; Richard O Day; Justin Pik; Stephen Jan; Laurent Billot; Chung-Wei Christine Lin Journal: Trials Date: 2013-07-11 Impact factor: 2.279
Authors: Stephanie Mathieson; Laurent Billot; Christopher G Maher; Andrew J McLachlan; Jane Latimer; Bart W Koes; Mark J Hancock; Ian Harris; Richard O Day; Justin Pik; Stephen Jan; Chung-Wei Christine Lin Journal: Trials Date: 2016-01-27 Impact factor: 2.279